Company
Headquarters: Beijing, China
Employees: 3,592
CN¥38.36 Billion
CNY as of July 1, 2025
US$5.35 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥6.13 B |
| EBITDA | CN¥2.53 B |
| Gross Profit TTM | CN¥3.21 B |
| Profit Margin | 24.10% |
| Operating Margin | 30.15% |
| Quarterly Revenue Growth | 7.80% |
Beijing Tiantan Biological Products Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600161 wb_incandescent